Cipla: It's not all that rosy - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: It's not all that rosy

Apr 21, 2004

Pharma major Cipla has announced its 4th quarter and annual results. The topline of the company has grown by 54% in the last quarter with net profit growing at a faster rate of 117%. For FY04, the performance of the company is nothing less than impressive. Net sales have risen by 31%.

Results at a glance…
(Rs m) 4QFY03 4QFY04 Change FY03 FY04 Change
Net sales 3,882 5,994 54.4% 15,728 20,600 31.0%
Other income 111 110 -1.1% 262 345 31.6%
Expenditure 3,411 4,702 37.8% 12,564 16,440 30.8%
Operating profit (EBDITA) 471 1,292 174.6% 3,163 4,160 31.5%
Operating profit margin (%) 12.1% 21.6%   20.1% 20.2%  
Interest 9 34 286.4% 17 102 495.3%
Depreciation 67 100 49.9% 284 365 28.7%
Profit before tax 506 1,267 150.6% 3,125 4,038 29.2%
Extraordinary items - - - - - -
Tax 38 250 551.0% 648 900 39.0%
Profit after tax/(loss) 467 1,017 117.7% 2,477 3,138 26.7%
Net profit margin (%) 12.0% 17.0%   15.8% 15.2%  
No. of shares (m) 60.0 60.0   60.0 60.0  
Diluted earnings per share (Rs)* 31.2 67.9   41.3 52.3  
P/E ratio (x)         25.3  
(* annualised)            

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 18, 2020 (Close)

TRACK CIPLA

CIPLA - ADCOCK INGRAM COMPARISON

COMPARE CIPLA WITH

MARKET STATS